author-photo

Balazs Medgyasszay

4

Papers

112

Citations

Citation Trend

Filter By

Papers (3) Sort By

Journal Conference Others

Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (32)
Health-related quality of life for pembrolizumab (pembro) plus ipilimumab (ipi) versus pembro plus placebo in patients with metastatic NSCLC with PD-L1 tumor proportion score ≥ 50%: KEYNOTE-598.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy-induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomized phase 2 trials

2021 Cancer Medicine
Show All
- Source
- Cite
- Save
Citations (0)